Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Sep 01, 2024 1:59pm

109 Views

Post# 36204746

RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)

Good point. It's almost as if the big players don't go on to chat rooms to hear what's going on with the company.

It's a new-ish approach to oncology. We're front row when the MOA proves out. Google it and make sure you read a variety of sources. Getting your info from 1 or 2 places can be detrimental to your IQ.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals